Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT 6 receptor antagonists. Design, synthesis and biological evaluation

Prince, 2015, World Alzheimer report 2015: the global impact of dementia - an analysis of prevalence, incidence, cost and trends, Alzheimer’s Dis. Int., 84 Alzheimer’s Association, 2015, 2015 Alzheimer's disease facts and figures, Alzheimers. Dement., 11, 332, 10.1016/j.jalz.2015.02.003 Gauthier, 2010, Management of behavioral problems in Alzheimer's disease, Int. Psychogeriatr., 22, 346, 10.1017/S1041610209991505 Okura, 2011, Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study, J. Am. Geriatr. Soc., 59, 473, 10.1111/j.1532-5415.2011.03314.x Borisovskaya, 2014, Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies, Curr. Psychiatry Rep., 16, 1, 10.1007/s11920-014-0470-z Cummings, 2000, The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease, Int. J. Neuropsychopharmacol., 3, 21, 10.1017/S1461145700001917 U.S. Food and Drug Administration, 2005 U.S. Food and Drug Administration, 2008 Davies, 1976, Selective loss of central cholinergic neurons in Alzheimer's disease, Lancet, 2, 1403, 10.1016/S0140-6736(76)91936-X Contestabile, 2011, The history of the cholinergic hypothesis, Behav, Brain Res., 221, 334 Mohamed, 2011, Alzheimer's disease: emerging trends in small molecule therapies, Curr. Med. Chem., 18, 4299, 10.2174/092986711797200435 Rodda, 2012, Cholinesterase inhibitors and memantine for symptomatic treatment of dementia, BMJ, 344, 10.1136/bmj.e2986 Grossberg, 2005, Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease, Curr. Med. Res. Opin., 21, 1631, 10.1185/030079905X65402 Ramirez, 2014, Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status, Drugs, 74, 729, 10.1007/s40265-014-0217-5 Lecoutey, 2014, Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment, Proc. Natl. Acad. Sci. U. S. A., 111, E3825, 10.1073/pnas.1410315111 Benhamú, 2014, Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease, J. Med. Chem., 57, 7160, 10.1021/jm5003952 Geldenhuys, 2011, Role of serotonin in Alzheimer's disease: a new therapeutic target?, CNS Drugs, 25, 765, 10.2165/11590190-000000000-00000 Kohen, 2002, Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor, J. Neurochem., 66, 47, 10.1046/j.1471-4159.1996.66010047.x Hamon, 1999, Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors, Neuropsychopharmacology, 21, 68S Codony, 2011, 5-HT(6) receptor and cognition, Curr. Opin. Pharmacol., 11, 94, 10.1016/j.coph.2011.01.004 Mitchell, 2005, 5-HT6 receptors: a novel target for cognitive enhancement, Pharmacol. Ther., 108, 320, 10.1016/j.pharmthera.2005.05.001 Fone, 2008, An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function, Neuropharmacology, 55, 1015, 10.1016/j.neuropharm.2008.06.061 Riemer, 2003, Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist, J. Med. Chem., 46, 1273, 10.1021/jm021085c Marcos, 2006, Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release, Eur. J. Neurosci., 24, 1299, 10.1111/j.1460-9568.2006.05003.x Dawson, 2001, The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus, Neuropsychopharmacology, 25, 662, 10.1016/S0893-133X(01)00265-2 Schechter, 2008, Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466, Neuropsychopharmacology, 33, 1323, 10.1038/sj.npp.1301503 Yun, 2011, The Serotonin-6 receptor as a novel therapeutic target, Exp. Neurobiol., 20, 159, 10.5607/en.2011.20.4.159 Woolley, 2001, A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze, Neuropharmacology, 41, 210, 10.1016/S0028-3908(01)00056-9 West, 2009, Activation of the 5-HT6 receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus, Neuroscience, 164, 692, 10.1016/j.neuroscience.2009.07.061 Myhrer, 2003, Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks, Brain Res. Rev., 41, 268, 10.1016/S0165-0173(02)00268-0 Wesołowska, 2010, Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data, Pharmacol. Rep., 62, 564, 10.1016/S1734-1140(10)70315-7 Bali, 2015, Serotonergic 5-HT6 receptor antagonists: heterocyclic chemistry and potential therapeutic significance, Curr. Top. Med. Chem., 15, 1643, 10.2174/1568026615666150427110420 Upton, 2008, 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease, Neurotherapeutics, 5, 458, 10.1016/j.nurt.2008.05.008 Wilkinson, 2014, Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial, Lancet. Neurol., 13, 1092, 10.1016/S1474-4422(14)70198-X Morphy, 2005, Designed multiple ligands. An emerging drug discovery paradigm, J. Med. Chem., 48, 6523, 10.1021/jm058225d Morphy, 2004, From magic bullets to designed multiple ligands, Drug Discov. Today, 9, 641, 10.1016/S1359-6446(04)03163-0 Guzior, 2015, Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease, Curr. Med. Chem., 22, 373, 10.2174/0929867321666141106122628 Więckowska, 2015, Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo, Bioorg. Med. Chem., 23, 2445, 10.1016/j.bmc.2015.03.051 Bajda, 2013, Structure-based search for new inhibitors of cholinesterases, Int. J. Mol. Sci., 14, 5608, 10.3390/ijms14035608 Więckowska, 2010, Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterases inhibitors, Eur. J. Med. Chem., 45, 5602, 10.1016/j.ejmech.2010.09.010 Kołaczkowski, 2014, Novel arylsulfonamide derivatives with 5-HT6/5-HT7 receptor antagonism targeting behavioral and psychological symptoms of dementia, J. Med. Chem., 57, 4543, 10.1021/jm401895u Kołaczkowski, 2015, Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia, Eur. J. Med. Chem., 92, 221, 10.1016/j.ejmech.2014.12.045 Kelly, 2002 Xiao, 2000, Huperzine A and tacrine attenuate β-amyloid peptide-induced oxidative injury, J. Neurosci. Res., 61, 564, 10.1002/1097-4547(20000901)61:5<564::AID-JNR11>3.0.CO;2-X Ezoulin, 2007, A new acetylcholinesterase inhibitor with anti-PAF activity modulates oxidative stress and pro-inflammatory mediators release in stimulated RAW 264.7 macrophage cells. Comparison with tacrine, Int. Immunopharmacol., 7, 1685, 10.1016/j.intimp.2007.08.023 Sola, 2015, Novel levetiracetam derivatives that are effective against the Alzheimer-like phenotype in mice: synthesis, in vitro, ex vivo, and in vivo efficacy studies, J. Med. Chem., 58, 6018, 10.1021/acs.jmedchem.5b00624 Hamulakova, 2014, Synthesis and biological evaluation of novel tacrine derivatives and tacrine-coumarin hybrids as cholinesterase inhibitors, J. Med. Chem., 57, 7073, 10.1021/jm5008648 Nepovimova, 2014, Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects, J. Med. Chem., 57, 8576, 10.1021/jm5010804 Fernández-Bachiller, 2012, New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties, J. Med. Chem., 55, 1303, 10.1021/jm201460y Galdeano, 2012, Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases, J. Med. Chem., 55, 661, 10.1021/jm200840c Xie, 2015, Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease, Eur. J. Med. Chem., 95, 153, 10.1016/j.ejmech.2015.03.040 Minarini, 2013, Multifunctional tacrine derivatives in Alzheimer's disease, Curr. Top. Med. Chem., 13, 1771, 10.2174/15680266113139990136 Chen, 2012, Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors, J. Med. Chem., 55, 4309, 10.1021/jm300106z Wang, 2012, Multifunctional mercapto-tacrine derivatives for treatment of age-related neurodegenerative diseases, J. Med. Chem., 55, 3588, 10.1021/jm300124p Belluti, 2009, Design, synthesis, and evaluation of benzophenone derivatives as novel acetylcholinesterase inhibitors, Eur. J. Med. Chem., 44, 1341, 10.1016/j.ejmech.2008.02.035 Samadi, 2013, Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease, Eur. J. Med. Chem., 67, 64, 10.1016/j.ejmech.2013.06.021 Guzior, 2015, Development of multifunctional, heterodimeric isoindoline-1,3-dione derivatives as cholinesterase and β-amyloid aggregation inhibitors with neuroprotective properties, Eur. J. Med. Chem., 92, 738, 10.1016/j.ejmech.2015.01.027 Bolea, 2011, J. Med. Chem., 54, 8251, 10.1021/jm200853t Kryger, 1998, Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica, J. Physiol., 92, 191, 10.1016/S0928-4257(98)80008-9 Kryger, 1999, Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs, Structure, 7, 297, 10.1016/S0969-2126(99)80040-9 Ellman, 1961, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol., 7, 88, 10.1016/0006-2952(61)90145-9 Di, 2003, High throughput artificial membrane permeability assay for blood–brain barrier, Eur. J. Med. Chem., 38, 223, 10.1016/S0223-5234(03)00012-6 Van der Laan, 1985, The effects of centrally acting adrenergic agonists on temperature and on explorative and motor behaviour. Relation with effects on quasi-morphine withdrawal behaviour, Eur. J. Pharmacol., 107, 367, 10.1016/0014-2999(85)90264-X Kassai, 2012, Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression, Behav. Pharmacol., 23, 397, 10.1097/FBP.0b013e3283565248 Furuie, 2013, MK-801-induced and scopolamine-induced hyperactivity in rats neonatally treated chronically with MK-801, Behav. Pharmacol., 24, 678, 10.1097/FBP.0000000000000003 Lavreysen, 2015, Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813, Pharmacol. Res. Perspect., 3, e00097, 10.1002/prp2.97 Rydberg, 2006, Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge, J. Med. Chem., 49, 5491, 10.1021/jm060164b Camps, 2008, Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation, J. Med. Chem., 51, 3588, 10.1021/jm8001313 Sun, 2013, Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids, Bioorg. Med. Chem., 21, 7406, 10.1016/j.bmc.2013.09.050 Savini, 2003, Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors, J. Med. Chem., 46, 1, 10.1021/jm0255668 Torres-Murro, 2005, Regioselective alkylation of 3,4-dihydro-2H-pyran by xanthate-mediated free radical nonchain process, Tetrahedron Lett., 46, 7691, 10.1016/j.tetlet.2005.09.049 Cappelli, 2011, Synthesis and structure-activity relationship studies in translocator protein ligands based on a pyrazolo[3,4-b]quinoline scaffold, J. Med. Chem., 54, 7165, 10.1021/jm200770f Decker, 2004, Investigations into the mechanism of lactamization of lactones yielding in a novel route to biologically active tryptamine derivatives, Tetrahedron, 60, 4567, 10.1016/j.tet.2004.03.073 Alanine, 1989, Facile preparation of 2-imino tetrahydrofurans, pyrans and oxepans, Tetrahedron Lett., 30, 6571, 10.1016/S0040-4039(01)89024-9 Zhang, 2010, Salicylic acid based small molecule inhibitor for the oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2), J. Med. Chem., 53, 2482, 10.1021/jm901645u Kołaczkowski, 2013, Ligand-optimized homology models of D1 and D2 dopamine receptors: application for virtual screening, J. Chem. Inf. Model, 53, 638, 10.1021/ci300413h Wang, 2013, Structural basis for molecular recognition at serotonin receptors, Science, 340, 610, 10.1126/science.1232807 Kurowski, 2003, GeneSilico protein structure prediction meta-server, Nucleic Acids Res., 31, 3305, 10.1093/nar/gkg557 Arnold, 2006, The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling, Bioinformatics, 22, 195, 10.1093/bioinformatics/bti770 D.C. Cole, M. Asselin, Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-Hydroxytryptamine-6 ligands, US Patent 2005/0101596, 2005.